Physician profile
David A Dean
NPI 1851391403
$1,627.31
in general payments reported to CMS, 2019-2025
11 companies · $229 in 2025
The $229 reported for 2025 was less than what a typical Thoracic Surgery (Cardiothoracic Vascular Surgery) provider received nationally (typical 2025 total: $796).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102 · 2020: $87.57 · 2021: $433 · 2022: $560 · 2023: $145 · 2024: $71.76 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $445.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $887.88 | 2019-2022 | |
| Atricure, INC. | $253.08 | 2022-2025 | Atriclip Laa Exclusion System |
| Terumo Medical Corporation | $195.03 | 2021 | |
| Cvrx, INC. | $76.82 | 2025 | Barostim Neo System |
| Abiomed | $70.36 | 2025 | |
| Depuy Synthes Sales INC. | $60.74 | 2025 | Matrixrib |
| Edwards Lifesciences Corporation | $26.64 | 2020 | |
| Solventum Corporation | $18.26 | 2024 | Activ.A.C. |
| Kestra Medical Technology Services, INC. | $13.15 | 2022 | |
| Pfizer INC. | $13.08 | 2019 | |
| Hemosonics LLC | $12.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Dean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.